Kate Bingham

Partner
SV Health Investors

Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. Kate’s investments, many of which are examples of SV’s company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU and US. Her investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

From May to December 2020 Kate served as Chair of the UK Vaccine Taskforce (VTF), which was set up in response to the COVID-19 pandemic to lead the UK’s efforts to discover and manufacture a COVID-19 vaccine. She was awarded a Dame Commander (DBE) rank in the Queen’s Birthday Honors in June 2021 for services relating to the procurement, manufacture, and distribution of COVID-19 vaccines. In her 30 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.

Kate serves on the Board of the Francis Crick Institute and won the BioIndustry Association UK Lifetime Achievement Award in January 2017. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate has a first-class degree in Biochemistry from Oxford University and an M.B.A. from Harvard Business School, where she was a Baker Scholar.